-
Venetoclax, sold
under the
brand names Venclexta and Venclyxto, is a
medication used to
treat adults with
chronic lymphocytic leukemia (CLL),
small lymphocytic...
-
selective inhibitor venetoclax (ABT-199),
which inhibits Bcl-2, but not Bcl-xL or Bcl-w.
Clinical trials studied the
effects of
venetoclax, a BH3-mimetic drug...
- (BCL-2) inhibitor,
venetoclax, plus a CD20
antibody obinutuzumab, OR BTKi (i.e. ibrutinib) plus BCL-2
inhibitor (i.e.
venetoclax) CLL is the most common...
- 2017, 12 new
agents have been
approved for AML in the U.S.,
including venetoclax (BCL2 inhibitor),
gemtuzumab ozogamicin (CD33 antibody-drug conjugate)...
- used to
treat DLBCL-RT. Recently,
small molecule anti-cancer
drugs (e.g.
venetoclax, atezolizumab, duvelisib, ublituximab, zanubrutinib, obinutuzumab, olatuzumab...
- to be one of the most up-regulated (i.e. overactive)
genes in BPDCN.
Venetoclax inhibits the apoptosis-inhibiting
action of BCL-2 and
proved active in...
- variant,
which limits the
effectiveness of first-generation
inhibitors like
venetoclax. "Sonrotoclax - BeiGene". AdisInsight.
Springer Nature Switzerland AG...
-
mepesuccinate L01XX41
Eribulin L01XX44
Aflibercept L01XX46
Olaparib L01XX52
Venetoclax L01XX53
Vosaroxin L01XX57
Plitidepsin L01XX58
Epacadostat L01XX66 Selinexor...
-
juvenile myelomonocytic leukemia. The
combination of
azacitidine and
venetoclax is also
approved for AML.
Azacitidine is a
chemical analogue of the nucleoside...
-
about 15-20% of
multiple myeloma patients) may
particularly benefit from
Venetoclax therapy (which is FDA
approved for
other blood cancers but not yet available...
